KR20230042030A - 항-IgE 조작된 항체 및 이의 적용 - Google Patents
항-IgE 조작된 항체 및 이의 적용 Download PDFInfo
- Publication number
- KR20230042030A KR20230042030A KR1020237003490A KR20237003490A KR20230042030A KR 20230042030 A KR20230042030 A KR 20230042030A KR 1020237003490 A KR1020237003490 A KR 1020237003490A KR 20237003490 A KR20237003490 A KR 20237003490A KR 20230042030 A KR20230042030 A KR 20230042030A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- antigen
- binding protein
- ser
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010663029 | 2020-07-10 | ||
| CN202010663029.3 | 2020-07-10 | ||
| CN202110750959.7 | 2021-07-01 | ||
| CN202110750959 | 2021-07-01 | ||
| PCT/CN2021/105620 WO2022007965A1 (zh) | 2020-07-10 | 2021-07-09 | 一种抗IgE的工程化抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230042030A true KR20230042030A (ko) | 2023-03-27 |
Family
ID=79552269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237003490A Pending KR20230042030A (ko) | 2020-07-10 | 2021-07-09 | 항-IgE 조작된 항체 및 이의 적용 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230250191A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4180454A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023541217A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230042030A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116018352A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021306786A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023000400A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3185192A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299747A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI896700B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022007965A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318098A (en) | 2022-07-01 | 2025-02-01 | Alk Abell? As | IGE-FCER pushers |
| CN116143932B (zh) * | 2022-12-07 | 2025-02-11 | 南开大学 | 一种针对IgE的抗体或其抗原结合片段以及Fc变体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1260521B1 (en) | 1991-08-14 | 2007-11-21 | Genentech Inc. | Immunoglobulin variants for specific Fc epsilon receptors |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| US20180273626A1 (en) * | 2015-09-11 | 2018-09-27 | The Board Of Trustees Of The Leland Stanford Junio University | Omalizumab resistant ige variants and their use in anti-ige therapy |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| EP4342541A3 (en) * | 2017-04-07 | 2024-07-03 | Kookmin University Industry Academy Cooperation Foundation | Antibody fc variants for increased blood half-life |
| KR20220098056A (ko) * | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| EP3788078A4 (en) * | 2018-05-04 | 2022-03-02 | Allakos Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA |
-
2021
- 2021-07-09 EP EP21836979.1A patent/EP4180454A4/en active Pending
- 2021-07-09 KR KR1020237003490A patent/KR20230042030A/ko active Pending
- 2021-07-09 CA CA3185192A patent/CA3185192A1/en active Pending
- 2021-07-09 IL IL299747A patent/IL299747A/en unknown
- 2021-07-09 JP JP2023501419A patent/JP2023541217A/ja not_active Ceased
- 2021-07-09 BR BR112023000400A patent/BR112023000400A2/pt unknown
- 2021-07-09 US US18/004,959 patent/US20230250191A1/en active Pending
- 2021-07-09 WO PCT/CN2021/105620 patent/WO2022007965A1/zh not_active Ceased
- 2021-07-09 AU AU2021306786A patent/AU2021306786A1/en active Pending
- 2021-07-09 TW TW110125327A patent/TWI896700B/zh active
- 2021-07-09 CN CN202180049003.2A patent/CN116018352A/zh active Pending
-
2026
- 2026-02-05 JP JP2026017958A patent/JP2026071342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230250191A1 (en) | 2023-08-10 |
| EP4180454A4 (en) | 2024-10-02 |
| IL299747A (en) | 2023-03-01 |
| TWI896700B (zh) | 2025-09-11 |
| JP2026071342A (ja) | 2026-04-28 |
| CN116018352A (zh) | 2023-04-25 |
| WO2022007965A1 (zh) | 2022-01-13 |
| CA3185192A1 (en) | 2022-01-13 |
| EP4180454A9 (en) | 2023-07-26 |
| EP4180454A1 (en) | 2023-05-17 |
| AU2021306786A1 (en) | 2023-02-16 |
| BR112023000400A2 (pt) | 2023-03-21 |
| JP2023541217A (ja) | 2023-09-29 |
| TW202214703A (zh) | 2022-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107849136B (zh) | 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 | |
| JP2021035365A (ja) | 抗トランスフェリン受容体抗体及びその使用方法 | |
| EP3262075B1 (en) | Novel antibody binding to tfpi and composition comprising the same | |
| BRPI0712953A2 (pt) | anticorpos anti-nkg2a e suas utilizações | |
| US11370836B2 (en) | Monoclonal antibody binding to human IL-5, preparation method therefor and use thereof | |
| CN101932606A (zh) | 对冯维勒布兰德氏因子特异的人源化抗体 | |
| EP3620472A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
| CN108473568A (zh) | 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子 | |
| KR102862077B1 (ko) | 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체 | |
| KR20220071264A (ko) | 항-pd-l1 항원 결합 단백질 및 이의 응용 | |
| JP2026071342A (ja) | 抗IgE改変抗体及びその適用 | |
| IL297638A (en) | Compounds and methods targeting interleukin-34 | |
| IL310427A (en) | Pharmaceutical composition of anti-il4r antibody and use thereof | |
| AU2023315149A1 (en) | Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof | |
| CN113366020B (zh) | 抗pd-l1的新型抗体及其用途 | |
| JP2025503707A (ja) | ガレクチン-10抗体 | |
| CN113164601B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| WO2024079482A1 (en) | Vegf antibodies | |
| JP2026513302A (ja) | 抗il-25抗体及びその使用方法 | |
| WO2026017189A2 (zh) | 抗il-31抗体、其药物组合物及用途 | |
| BR122024025202A2 (pt) | Anticorpos multiespecíficos, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir anticorpos multiespecíficos, composição farmacêutica e uso | |
| HK40044251A (en) | Monoclonal antibody binding to human il-5, preparation method therefor and use thereof | |
| HK1141039B (en) | Fully human anti-vap-1 monoclonal antibodies | |
| HK1141039A1 (en) | Fully human anti-vap-1 monoclonal antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |